April 2014, 22:7

04 December 2014

Debate

Debate

Opposition: Unfractionated heparin should no longer be used in the catheterization laboratory

Moo Hyun Kim, Young Seok Lee, Michael S. Lee

ASEAN Heart Journal

First online: 

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

Introduction

The goal of anticoagulation during percutaneous coronary intervention (PCI) is the primary and secondary prevention of thrombotic and significant bleeding events that increase cardiovascular morbidity and mortality. Unfractionated heparin is the most commonly-used anticoagulant, but low-molecular weight heparin, and more recently bivalirudin are becoming increasingly popular in cardiac catheterization laboratories(1).

The ACC/AHA/SCAI PCI guidelines2 recommend a 70-100 IU/kg bolus of heparin to achieve an activated clotting time (ACT) of 250-300 seconds for Hemotec and 300-350 seconds for Hemochron systems, when glycoprotein IIb/IIIa inhibitors are not used. When glycoprotein IIb/IIIa inhibitors are used, a bolus of 50-70 IU/kg of unfractionated heparin is recommended to achieve an ACT of 200-250 seconds.

Keywords

Percutaneous Coronary Intervention - Enoxaparin - Unfractionated Heparin - Fondaparinux - Bivalirudin

 

__________________________________________________________________________________

 

Moo Hyun Kim, Director, Regional Clinical Trial Center, Professor; Dept. of Cardiology, Dong-A University Hospital, 3-1, Dongdaeshin-Dong, Seo-Gu, Busan, Korea 602-715

Open Access: This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research